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ABSTRACT
Proprotein convertases (PCSK) have a critical role in the body homeostasis as enzymes responsible for
processing precursor proteins into their mature forms. FURIN, the ﬁrst characterized member of the
mammalian PCSK family, is overexpressed in multiple malignancies and the inhibition of its activity has
been considered potential cancer treatment. FURIN has also an important function in the adaptive
immunity, since its deﬁciency in T cells causes an impaired peripheral immune tolerance and accelerates
immune responses. We addressed whether deleting FURIN from the immune cells would strengthen
anticancer responses by subjecting mouse strains lacking FURIN from either T cells or macrophages and
granulocytes to the DMBA/TPA two-stage skin carcinogenesis protocol. Unexpectedly, deﬁciency of FURIN
in T cells resulted in enhanced and accelerated development of tumors, whereas FURIN deletion in
macrophages and granulocytes had no effect. The epidermises of T-cell-speciﬁc FURIN deﬁcient mice were
signiﬁcantly thicker with more proliferating Ki67C cells. In contrast, there were no differences in the
numbers of the T cells. The ﬂow cytometric analyses of T-cell populations in skin draining lymph nodes
showed that FURIN T-cell KO mice have an inherent upregulation of early activation marker CD69 as well
as more CD4CCD25CFoxp3C positive T regulatory cells. In the early phase of tumor promotion, T cells from
the T-cell-speciﬁc FURIN knockout animals produced more interferon gamma, whereas at later stage the
production of Th2- and Th17-type cytokines was more prominent than in wild-type controls. In conclusion,
while PCSK inhibitors are promising therapeutics in cancer treatment, our results show that inhibiting
FURIN speciﬁcally in T cells may promote squamous skin cancer development.
Abbreviations: CTL, cytotoxic T lymphocyte; dLN, draining lymph node; DMBA, 7,12-Dimethylbenz[a]anthracene;
IFNg , interferon gamma; IL, interleukin; KO, knockout; LysM, lysozyme-M; OVA, ovalbumin; PCSK, proprotein conver-
tase; TCR, T-cell receptor; TGF-b1, transforming growth factor-b1; TPA, 12-O-tetradecanoylphorbol-13-acetate; Treg,
regulatory T cell; VEGF, vascular endothelial growth factor
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Introduction
The mammalian proprotein convertase (PCSK) family consists
of nine members. The primarily identiﬁed seven PCSKs
(PCSK1-2, FURIN, PCSK4-7) are closely related and evolution-
arily conserved subtilisin/kexin-like serine proteases that con-
vert their immature substrates into functional end-products by
cleaving basic amino acid motifs ((K/R)-(X)n-(K/R)#, where n
is 0, 2, 4, or 6 and X is any amino acid).1 PCSKs operate mainly
in the secretory pathway, on the cell surface and in the endo-
somes. More recently identiﬁed and distantly related PCSK
family members MBTPS1 and PCSK9 differ from the seven
other members in their target sequence speciﬁcities. MBTPS1
targets a consensus motif (R/K)-X-(hydrophobic)-X# and
PCSK9 has only autocatalytic cleavage activity.2
PCSK enzymes play an instrumental role in maintaining
homeostasis in the body but also in a number of pathological con-
ditions.2 Various PCSK target proteins are involved in malignant
transformation and progression. PCSKs activate for example cell
surface-expressed receptors (e.g., integrins), tissue-modifying
enzymes like matrix metalloproteinases3-5 and growth factors
needed to support tumor angiogenesis, including vascular endo-
thelial growth factors (VEGF) C and D.6,7 Many human cancers
show high levels of PCSK expression (reviewed in ref.8). For exam-
ple, FURIN expression is elevated in non-small cell lung
CONTACT Marko Pesu marko.pesu@uta.ﬁ Immunoregulation, BioMediTech, University of Tampere, Lääkärinkatu 1, FI-33520 Tampere, Finland;
Tero A. J€arvinen tero.ah.jarvinen@uta.ﬁ School of Medicine, Department of Anatomy and Cell Biology, University of Tampere, Lääkärinkatu 1, FI-33520 Tampere,
Finland.
Supplemental data for this article can be accessed on the publisher’s website.
*These authors contributed equally.
#Equal contribution and corresponding authors.
Published with license by Taylor & Francis Group, LLC © Maria V€ah€atupa, Saara Aittom€aki, Zuzet Martinez Cordova, Ulrike May, Stuart Prince, Hannele Uusitalo-J€arvinen, Tero J€arvinen and Marko Pesu.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which per-
mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
ONCOIMMUNOLOGY
2016, VOL. 5, NO. 12, e1245266 (11 pages)
http://dx.doi.org/10.1080/2162402X.2016.1245266
carcinoma as well as in human head and neck squamous cell car-
cinomas, and the upregulated FURIN activity correlates with
accelerated tumor progression.9-11 Transgenic overexpression of
FURIN in mouse epidermal basal layer resulted in increased papil-
loma and squamous cell carcinoma development and enhanced
tumor growth when the mice were subjected to a two-stage chem-
ical carcinogenesis protocol12. In line with that data, deleting
FURIN from mouse salivary gland cells also delayed PLAG1-
induced salivary gland tumorigenesis.13
PCSK enzymes are also key regulators of the immune system.
By using a conditional, T-cell-speciﬁc FURIN deﬁcient mouse
(CD4cre-furﬂox/ﬂox) we have shown that T-cell-expressed FURIN
is critical for maintaining peripheral tolerance.14 T-cell-speciﬁc
FURIN deletion causes age-related autoimmunity, with expan-
sion and overactivation of effector T cells, excessive production
of pro-inﬂammatory cytokines, and functionally defective regula-
tory T cells (Treg). The autoimmune phenotype in FURIN T-
cell KO mice could be at least partially attributed to reduced lev-
els of bioactive, anti-inﬂammatory cytokine transforming growth
factor-b1 (TGF-b1), which is a known FURIN substrate mole-
cule.15 Furthermore, we have recently demonstrated that FURIN
directly regulates T-cell activation by modifying the TCR-
induced transactivation steps.16
The implication of PCSKs as regulators of tumor progression
and metastasis has provoked an interest to use them as targets of
novel anticancer agents. Based on our previous ﬁndings, inhibi-
tion of FURIN activity in immune cells could be an effective
way of boosting antitumor host responses. Thus, we investigated
how the immune-cell-expressed FURIN regulates tumorigenesis
by using mouse strains with a conditional deletion of FURIN
either in T cells or in myeloid cells (CD4cre and LysMcre,
respectively) in the two-stage chemical DMBA/TPA-induced
skin carcinoma model. Our data demonstrate that FURIN
expression in T cells, but not in myeloid cells, constrains the
DMBA/TPA-induced development of squamous skin cancer.
Results
T-cell-expressed FURIN inhibits skin tumor induction
Targeting PCSK, and in particular, FURIN activity, has been
considered a promising cancer treatment.17 However, the
germ-line deletion of FURIN causes embryonic lethality, which
confounds the studies on its in vivo functions in cancer
research.18 Therefore, the cell-type-speciﬁc function of FURIN
in carcinogenesis has remained incompletely understood. To
investigate if the immune-cell-expressed FURIN controls skin
tumor formation, we treated the back skin of adult mice deﬁ-
cient for FURIN gene expression either in macrophages and
granulocytes (designated LysMcre KO19,40) or in CD4C and
CD8C T cells (designated CD4cre KO,14) and their respective
wild-type littermates (LysM WT and CD4C WT) once with a
local application of the mutagen DMBA, and then with the
growth-promoting agent TPA, twice weekly for a period of 16
and 21 weeks. This treatment induces papillomas derived from
the interfollicular epidermis.20
FURIN protein expression was detected in untreated and
DMBA/TPA-treated skin in CD4C WT mice (Fig. S1). In nor-
mal skin, FURIN was expressed abundantly in the epidermis
and some resident cells in the dermis were also positive for
FURIN expression. DMBA/TPA application induced FURIN
mRNA expression and resulted in a strong accumulation of
FURIN expressing cells in the dermal part of the skin (Fig. S1).
Unexpectedly, deletion of FURIN speciﬁcally from T cells
resulted in the development of more papillomas (p < 0.0001,
Fig. 1A). The ﬁrst papillomas were observed in the CD4cre KO
mice 8 weeks after the beginning of the DMBA/TPA treatment,
and after 9 weeks, all of the CD4cre KO mice had developed
papillomas on their back skin. The ﬁrst papillomas were identi-
ﬁed in both WT control strains as well as in the LysMcre FURIN
KO mice after 10–12 weeks of treatment (Fig. 1A). Furthermore,
the CD4cre KO mice also developed signiﬁcantly more tumors
on their back skin than the other strains (p < 0.001, Fig. 1B).
Prior to euthanization (at 17 weeks due to ethical reasons), the
CD4cre KO mice had developed almost 20 papillomas per ani-
mal, whereas the WT controls had less than ﬁve papillomas on
average (Fig. 1B). In addition, both LysMcre KO and LysM WT
mice had a similar number of tumors at 17 weeks as CD4C WT
mice. The treatment of LysMcre KO and WT strains was contin-
ued for additional 5 weeks, but no differences in tumor forma-
tion could be detected (Fig. 1B). The tumors were incident in
CD4cre KO animals at a rate on average 4.6-fold greater than in
CD4C WT mice during the course of experiments (negative
binominal regression analysis:incidence rate ratio (IRR) D 4.6;
95% conﬁdence interval (CI) 1.97, 10.79).
Despite CD4cre KO mice were developing skin tumors
signiﬁcantly faster and in greater numbers than the other
strains, the papillomas in the CD4cre KO mice did not con-
tinue to grow in size (Fig. S2A). Instead, a large number of
small papillomas visibly disappeared and some converted
into chronic ulcers (Fig. S2B). We could not detect similar
ulcers in CD4C WT, LysMcre KO, and LysM WT strains
(Fig. 1C and Fig. S2). The histological analysis revealed that
the ulcers in CD4cre KO mice had papilloma formations,
but also ruptured epidermis and clusters of neutrophils as a
sign of compromised physical integrity of the skin (Fig. S2F).
In conclusion, the lack of FURIN in T cells, but not in
LysMC myeloid cells, promotes tumor induction and forma-
tion in the DMBA/TPA-induced skin cancer. This prompted
us to further characterize the role of T-cell-expressed FURIN
in squamous skin cancer immunosurveillance.
The susceptibility to tumor formation in CD4cre FURIN KO
mice is associated with enhanced cell proliferation, but not
with vascularization
To understand the mechanism of the skin tumor-inhibiting
function of T-cell-expressed FURIN, we ﬁrst performed histolog-
ical analyses to determine the epidermal and dermal thicknesses,
cell proliferation (Ki67) and apoptosis (TUNEL) frequency in
the back skin of DMBA/TPA treated and untreated mice.
In untreated mice, loss of FURIN from T cells resulted in a sig-
niﬁcant thickening of the epidermis (Fig. S3A). Treatment with
DMBA/TPA induced a substantial increase (p< 0.001) in the epi-
dermal thickness in both genotypes (both epidermises p < 0.0001
over untreated skin), and approximately a 30% increase in the
thickness of the epidermis persisted in the CD4cre KO mice over
the CD4CWTmice (p< 0.0001, Fig. S3A). In contrast, signiﬁcant
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differences were not detected in the dermal thicknesses of
untreated or treated animals (Fig. S3B).
CD4cre KO mice had also signiﬁcantly more proliferating
cells (as determined by Ki67-positivity) than WT mice in the
epidermis of the untreated skin (p < 0.0001, Fig. S3C). After 17
weeks of DMBA/TPA treatment, the CD4cre KO mice had
more proliferating cells in both epidermal and dermal parts of
the skin (p < 0.001 and p D 0.0056, Figs. S3C and D). In con-
trast, there was no difference in the cell proliferation rate in the
papilloma tissue (or the dermis beneath it) (Figs. S3C and D).
TUNEL staining demonstrated that CD4cre KO mice had less
apoptotic cells in untreated dermis (p < 0.05, Fig. S4A), but a
prolonged DMBA/TPA-treatment (17 weeks) reduced signiﬁ-
cantly the numbers of dying cells in both genotypes (epidermis,
p < 0.0001, dermis p < 0.0001, Fig. S4).
As the availability of vascular supply is a limiting factor for
tumor growth and FURIN has a substantial inﬂuence on angio-
genesis,6,7 we also examined the vasculature in the skin. Angiogen-
esis is turned on already in the earliest stages of papilloma
formation and in late stages the blood vessels start to increase in
size.21 There were slightly more blood vessels in CD4cre KO mice
in the untreated skin compared to WT as determined by an
immunohistological analysis of endothelial cell marker CD31
(Fig. S5A). A 17-week treatment with DMBA/TPA induced a 2-
fold increase in the vascular density of the skin only in CD4CWT
mice (p < 0.0001), whereas in CD4cre KO the vascular density
was signiﬁcantly smaller (p < 0.0001, Fig. S5A). Despite the fact
that non-tumorous WT skin had signiﬁcantly more blood vessels
than in the CD4cre KO mice after the DMBA/TPA treatment, the
tumor formation required vascular supply in both genotypes as
evidenced by the increased number of blood vessels beneath the
tumors (p < 0.0001, Fig. S5). In conclusion, the accelerated
tumorigenesis in CD4cre KO mice was not found to be associated
with increased angiogenesis.
Mice lacking FURIN in T cells have an attenuated
macrophage extravasation or differentiation response to
DMBA/TPA treatment
Previous work has shown that tumorigenesis in the DMBA/
TPA model is promoted upon the induction of acute
inﬂammation in the skin at the sites of chemical applica-
tion.22,23 To investigate if the CD4cre KO mice had an
enhanced skin inﬂammatory response, we ﬁrst quantiﬁed
skin CD3C T cells as well as the numbers of inﬁltrating F4/
80C macrophages and elastase positive neutrophils. There
were signiﬁcantly more CD3C T cells in the CD4cre KO
mice than in littermate controls in both untreated skin
(p < 0.0001) and at 43 h post DMBA/TPA treatment (p <
0.05), but after 17 weeks T cell numbers were similar
(Figs. 2A and B). In contrast, the numbers of macrophages
were more readily induced in KO mice at 43-h time-point,
but interestingly this was reverted at later stages; after a 17-
week treatment CD4cre KO mice showed signiﬁcantly
reduced macrophage counts in non-tumorous skin (p <
0.001, Figs. 2C and D). The signiﬁcantly lower number of
macrophages in the CD4cre KO skin was especially evident
underneath the papillomas, where the KO mice had only
ca. twenty-ﬁve percent of the macrophages seen in the WT
dermis (Figs. 2C and D). No signiﬁcant differences were
Figure 1. T-cell-speciﬁc deletion of FURIN accelerates skin tumor formation. Wild-type (LysM WT and CD4C WT), T-cell (CD4cre) and macrophage and neutrophil-speciﬁc
(LysMcre) knockout mice were subjected to DMBA/TPA-induced skin carcinogenesis. (A) The percentage of tumor-free animals at each time point is shown. Survival plot
was generated and analyzed via log-rank (Mantel-Cox) test. (B) The mean number of tumors per mouse at each time point is shown § standard error of the mean. The
data were analyzed using STATA 13.0 software. A non-linear regression model was used to compare the slopes of the data. (C) Representative photograph of a CD4C WT
mouse at week 13 of the DMBA/TPA treatment trial, alongside a hematoxylin-eosin stained section of skin at week 17 (the black bar represents 2 mm). (D) Representative
photograph of a CD4cre KO mouse at week 13 of the DMBA/TPA treatment trial, alongside a hematoxylin-eosin stained section of skin at week 17 (the black bar repre-
sents 2 mm). CD4CWT nD 6, CD4cre KO n D 4, LysM WT nD5, and LysMcre KO nD 5.
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Figure 2. Immune cell numbers in the skin of WT and CD4cre FURIN KO mice. CD4C WT and CD4cre KO mice were subjected to DMBA/TPA-induced skin carcinogenesis as
described in methods. Skin samples were collected from untreated animals and from mice sacriﬁced at 43 h after the second TPA application, and after 17 weeks of treatment
(twice weekly). The skin samples were processed for IHC as described in methods. Skin sections were IHC stained for markers for T cells (CD3), macrophages (F4/80), and neu-
trophils (neutrophil elastase). Results are shown as mean § 95% conﬁdence intervals. Data were analyzed by normality tests and unpaired two-tailed Student’s t-tests (Graph-
Pad Prism 6). The black bar in images represents 200 mm. Nuclei are stained blue, and immune cells brown. (A) Representative photographs of T cell staining in CD4C WT and
CD4cre KO skin. (B) Quantitative analyses of scanned slides were performed as described in supplementary methods. Data is expressed as % of total nuclei. (C) Representative
photographs of macrophage staining and (D) results of quantitative analyses of scanned slides. (E) Representative photographs of neutrophil staining and (F) results of quantita-
tive analyses of scanned slides. The information of animal numbers and analyzed tissue regions is shown in Table S1. (p < 0.0001; p < 0.001; p < 0.01; p < 0.05).
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observed in neutrophils between the genotypes (Figs. 2E
and F). Collectively these ﬁndings suggest that CD4cre KO
mice may have accelerated skin immune responses at the
early stage of cancer development, but this is later followed
by reduced macrophage presence in cancerous skin.
The skin-draining lymph node T cells lacking FURIN display
an activated phenotype
To gain speciﬁc information on the T-lymphocyte populations,
the skin draining lymph node (dLN) cells from CD4cre KO
mice and their WT littermate controls were subjected to ﬂow
cytometric analysis. There were no signiﬁcant differences in the
total CD4C T cell percentages (of total live cells) between the
untreated CD4cre KO and WT mice or between CD4cre KO
and WT mice treated with DMBA/TPA for 17 weeks (Fig. 3). In
untreated CD4cre KO mice, there were fewer dLN CD8C T cells
(percent of the live cells) than in the untreated WT controls, but
the difference was lost after the 17-week DMBA/TPA treatment.
However, the dLN T cells from the CD4cre KO animals dis-
played a more active phenotype, as signiﬁcantly higher propor-
tion of both CD4C and CD8C T cells from KO animals was
positive for CD69, a marker for recently activated cells (Fig. 3).
The analysis of T-cell memory phenotypes using CD44 and
CD62L antibodies demonstrated a signiﬁcantly higher percent-
age of central memory CD62LhighCD44high CD8C T cells (of
total CD8C T cells) in both untreated and 17-week-treated
CD4cre KO animals (Fig. 3). This is in parallel with a recent
report showing that blocking endogenous TGF-b1 signaling in
CD8C T cells enhances their conversion into central memory
cells.24 Since FURIN processes pro-TGF-b1, the autocrine TGF-
b1 signaling is likely to be defective in FURIN-deﬁcient CD8C
T cells. There were also signiﬁcantly more CD4CCD25CFoxp3C
Treg cells in the skin dLNs of CD4cre KO mice compared to
those of WT littermates, both from untreated mice and mice
treated with DMBA/TPA for 17 weeks (Fig. 3).
In conclusion, FURIN expression did not affect the numbers
of T cells in the skin dLN after a 17-week DMBA/TPA-treat-
ment, but T cells from the dLNs of the CD4C KO mice were
inherently more active and constituted more of cells with a
Treg phenotype, irrespective of the treatment. Therefore, the
increased susceptibility of CD4cre KO mice to develop papillo-
mas is not due to reduced dLN T-cell numbers or lack of T-cell
activation.
T cells lacking FURIN produce more interferon gamma in
the early phase of tumor development
To investigate the cytokine production of T cells in the early
phase of tumor development, we analyzed dLN T cells at 48 h
post the second TPA treatment by intracellular staining and
ﬂow cytometry. Both CD4C and CD8C effector T cells from the
CD4cre KO mice produced more pro-inﬂammatory interferon
gamma (IFNg) (Figs. 4B and C). On the other hand, there was
no difference in the production of another pro-inﬂammatory
cytokine, interleukin (IL) 17A (IL-17A), or in the CD4C T-cell-
produced IL-10, which is considered anti-inﬂammatory
(Figs. 4B and C). In order to gain information on the predomi-
nant type of immune response in the CD4cre KO mice and
their WT controls, we analyzed the systemic production of var-
ious chemokines, by performing a multiplex assay from the
sera 43 h post second TPA treatment. There were no obvious
differences in the levels of CCL2/MCP1, CXCL-1/GROa,
CCL11/Eotaxin, CXCL2/MIP-2, CCL7/MCP-3, CCL5/
RANTES, CCL3/MIP-1a, or CCL4/MIP-1b (data not shown),
but the level of CXCL10/IP-10 was elevated by 2-folds in
CD4cre KO sera compared to those of WT mice (p D 0.0711,
Fig. 4E). Collectively, these ﬁndings imply that in the early
Figure 3. Proﬁling of the skin draining lymph node T-cell populations in WT and
CD4cre KO mice. Cells were isolated from untreated mice and from animals treated
with a single application of DMBA and twice-weekly doses of TPA for 17 weeks,
and surface markers were analyzed by ﬂow cytometry. Frequency of cells among
total live cells or either CD4C or CD8C cell populations is shown, each symbol rep-
resenting an individual mouse, lines indicating the mean. Statistics were calculated
with unpaired two-tailed Student’s t-test (with Welch correction). Untreated mice:
n D 5 (for both genotypes), 17-week-treated CD4cre KO animals: n D 3, WT litter-
mate controls n D 4.
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phase of tumor development the FURIN T-cell-speciﬁc knock-
out mice have a Th1-type-skewed immune response.25
We also studied the production of IFNg, IL-17A, and IL-10
by CD4CFoxp3C Treg cells isolated from the dLNs of CD4cre
KO and WT mice. There was a trend toward a higher produc-
tion of IFNg in the Treg cells from the CD4cre KO animals (p
D 0.0592), and a signiﬁcant reduction in the percentage of
CD4cre KO Treg cells positive for IL-17A (p D 0.0066,
Fig. 4D). However, the percentage of dLN Treg cells producing
IL-10 was not different between the CD4cre KO and WT. Also
the mean ﬂuorescence intensity of the CD25 surface staining
was similar in Treg cells isolated from dLNs of both CD4cre
KO and WT mice indicating normal Treg activation status.
Collectively, the ﬂow cytometric analyses suggest that the
tendency of CD4cre KO animals to develop more papillomas
could be related to accelerated Th1-type immune responses.26
In contrast, despite CD4cre KO animals showing an increased
number of regulatory CD4CCD25CFoxp3C cells, these cells are
Figure 4. T cells from the skin draining lymph nodes of CD4cre KO mice show elevated IFNg production in the early phase of tumor development. Intracellular ﬂow
cytometry from skin draining lymph node cells. Mice were treated with one dose of DMBA, two doses of TPA on the back skin, then sacriﬁced after 48 h from the 2nd
TPA dose, and the isolated dLN cells were stimulated with TPA C Ca-ionomycin for 4 h in vitro. (A) Representative plots from CD4C WT and CD4cre KO mice, showing
live-gated cell populations positive for CD4C, Foxp3, IFNg, and IL-10. (B) Percentages of CD4C cells positive for IFNg , IL-17A, and IL-10. (C) CD8C cells positive for IFNg
and IL-17A. (D) CD4CFoxp3C Treg positive for IFNg , IL-17A, and IL-10, and the mean ﬂuorescence intensity (MFI) of CD25 from the Treg population. (E) CXCL10 levels
from sera from mice treated with TPA for 43 h, determined by the ProCartaPlex Mouse Cytokine & Chemokine 26-plex assay and Bio-Plex 200 instrument. B, C, D: CD4C
WT mice n D 6, CD4cre KO mice n D 7; E: CD4C WT mice n D 3, CD4cre KO mice n D 3. Each symbol represents an individual mouse, lines indicate the mean. Statistics:
Unpaired two-tailed Student’s t-test with Welch correction.
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likely defective in their suppressive activity as suggested by
upregulated CD69 expression and IFNg production in CD4C,
CD8C effector T cells, and Tregs. This conclusion is also sup-
ported by our previous data demonstrating impaired peripheral
Treg-dependent immune tolerance in CD4cre KO mice.14
In the later stage of carcinogenesis T-cell responses in the
FURIN deﬁcient T cells switch toward Th2 and Th17 type
In addition to T-cell activation, FURIN regulates the T helper
cell balance of the immune system.27,28 We proﬁled the levels
of multiple cytokines and chemokines from the cells isolated
from skin dLNs of the mice that had been treated with DMBA/
TPA for 17 weeks. Surprisingly, the cells from CD4cre KO
mice no longer produced elevated IFNg levels (like in the early
phase), but the production of Th2-type cytokine IL-13 and
Th17-type cytokine IL-22 was higher (p D 0.0219 and p D
0.0393, respectively, Fig. 5). Also, the levels of other Th2/Th17
cytokines, IL-4, IL-17A, IL-9, or IL-10 showed a trend toward
upregulated production in the CD4cre KO animals (Fig. 5).
QRT-PCR performed from the back skins conﬁrmed the switch
in Th responses, showing an upregulation of IFNg in the KO
animals in the early time points and of IL-17a in the late time
point (Fig. S6). The levels of IL-2 and tumor necrosis factor a
(TNFa) were lower in the dLN cells isolated from CD4cre KO
mice compared to those isolated from WT animals, as we have
previously shown in the untreated animals.14 Altogether, the
results suggest that during the course of carcinogenesis progres-
sion, the early Th1-biased immune responses of the T-cell-spe-
ciﬁc FURIN deﬁcient mice switch increasingly toward Th2 and
Th17 type responses. Thus, FURIN has an inherent role in
modulating T helper cell balance in a chronic immune insult.
Discussion
Various studies have shown that FURIN overexpression is
associated with accelerated carcinogenesis. Thus, its inhibition
could be a viable cancer treatment. However, the function of
Figure 5. FURIN-deﬁcient T cells show a Th2- and Th17-type cytokine proﬁle of in the late phase of tumor progression. CD4cre KO and WT mice were treated once with
DMBA, then with TPA for 17 weeks (twice a week) on the back skin as in Fig. 1. At 17 weeks, animals were sacriﬁced and skin draining lymph node cells were cultured for
48 h in the presence of plate-bound anti-CD3 and soluble anti-CD28 antibodies. Cytokine levels were determined from the culture supernatants with ProCartaPlex Mouse
Cytokine & Chemokine 26-plex assay and Bio-Plex 200 instrument, or for IFNg , with ELISA. Statistics: Unpaired two-tailed Student’s t-test with Welch correction. CD4C WT
nD 4, CD4cre KO n D 3. Each symbol represents an individual mouse, lines indicate the mean.
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FURIN in different cell types that contribute to tumor forma-
tion is poorly characterized. To study the role of FURIN in
immune cells in the context of squamous skin cancer develop-
ment, we utilized two mouse strains that lack FURIN speciﬁ-
cally either in macrophages and granulocytes or in T cells.
As our previous results have shown that FURIN-deﬁcient T
cells and macrophages display an overtly activated pheno-
type,14,19,40 we assumed that the FURIN-deﬁcient immune cells
might be more effective in anticancer immune responses. How-
ever, after being subjected to the DMBA/TPA treatment, mice
with the T-cell-speciﬁc knockdown of FURIN (CD4cre KO)
developed more papillomas and they appeared faster in the
knockout than their WT littermates. The CD4cre KO mice pre-
sented with a thicker epidermis, with more epidermal cell pro-
liferation than the WT mice, and this difference between the
genotypes was maintained after 17 weeks of DMBA/TPA treat-
ment. Under normal conditions, the CD4cre KO skin harbored
more CD3C T cells than the WT skin, but upon treatment that
difference was lost. Analysis of skin dLN cells showed no major
FURIN-dependent effects of the DMBA/TPA treatment on the
numbers of CD4C or CD8C T-cell populations. The higher
number of CD4CCD25CFoxp3C Tregs present in CD4cre KO
dLNs in the steady state persisted after the treatment, as did the
number of activated CD4CCD69C and CD8CCD69C T cells. In
the early phase of tumor promotion, the CD4cre KO mice had
more pro-inﬂammatory IFNg-producing T cells, whereas
CD4cre KO dLN cells secreted more Th2- and Th17-type cyto-
kines after 17 weeks of DMBA/TPA treatment (Fig. S7).
The fact that CD4cre KO, but not LysMcre KO, mice had an
increased susceptibility for papilloma development is in line with
several studies showing a tumor-enhancing role for ab T
cells.29,30 Previous work has demonstrated that IFNg promotes
tumor development primarily in the early stage of papilloma
development.26 IL-17A, in turn, has a role in the promotion pro-
cess in both human non-melanoma skin cancer and mouse mod-
els of skin cancer, suggesting that Th2- and Th17-type cytokine
proﬁle of the T cells lacking FURIN could be driving the carcino-
genesis process at later stages.31-33 LysMcre KO mice, in contrast,
display accelerated innate immunity responses, and a heterozy-
gous, inactivating mutation in the FurinA gene results in
enhanced innate responses inMycobacterium marinum –infected
zebraﬁsh.19,40 However, the pro-inﬂammatory phenotype due to
lack of FURIN in myeloid cells does not seem to play a major
role in the papilloma development in the DMBA/TPA-model.
FURIN and other PCSK family members play an important
role in carcinogenesis and metastasis, and there has been con-
siderable interest to develop pharmaceutical inhibitors of their
activity for cancer treatment. Inhibiting FURIN/PCSK is rea-
soned to directly block the processing of factors that are associ-
ated with tumor invasion and metastatic activity, including
matrix metalloproteinases, growth factors, and others. Further-
more, FURIN is critical for the activation of anti-inﬂammatory
cytokine TGF-b1. Thus, speciﬁc blocking of FURIN is thought
to support antitumor host-responses by promoting cancer
immunosurveillance. The assessment of a bifunctional GM-
CSF-FURINshRNA construct (FANGTM, VigilTM, Gradalis) has
already entered the phase II clinical trials for treatment of mela-
noma, ovarian cancer, and colorectal cancer with liver metasta-
sis.17,34 Recently, the shRNA-mediated inhibition of FURIN
together with dendritic cell supporting GM-CSF expression was
also found to be efﬁcacious in metastatic, advanced Ewing’s sar-
coma.35 In contrast, in liver cancers FURIN overexpression sup-
presses tumor growth and predicts better postoperative
survival.36 The beneﬁcial effect of FURIN in hepatocellular car-
cinoma was also reported in mice where FURIN was deleted
using liver speciﬁc Albumin CRE.37 It seems therefore plausible
that FURIN has tumor type-speciﬁc effects, and thus FURIN
inhibition systematically may not always be beneﬁcial for oncol-
ogy patients.
The role of FURIN in T-cell-dependent immunity is
clearly multifaceted. A major function of FURIN is to con-
trol the bioavailability of anti-inﬂammatory TGF-b1, and
Treg-dependent peripheral immune tolerance.14 TGF-b1 is
a multifunctional growth factor that has roles in both pro-
moting and suppressing tumorigenesis.38 Deleting TGF-b1
speciﬁcally from activated CD4C T cells and Treg cells
reduced metastatic B16-OVA tumor cell spread to the
mouse lung, indicating that activated CD4C T-cell-derived
TGF-b1 inhibits tumor immunosurveillance.39 Importantly,
we have also shown that FURIN is an important factor in
modulating the T helper cell balance. Mice that were chron-
ically infected with intracellular Toxoplasma gondii parasite
had less pathogen-speciﬁc Th1-type immune cells, and
na€ıve, OVA-speciﬁc FURIN KO CD4C T cells showed an
increased tendency to polarize into the IL-4-producing Th2
cells.27 The switch from Th1 into Th2/Th17-type responses
was also seen here in CD4cre KO mice after a 17-week
DMBA/TPA treatment. Thus, inhibiting FURIN does not
just promote T-cell-driven adaptive immunity, but it also
modulates the type of T helper cell responses. It is also
noteworthy that the regulatory role of FURIN in CD8C
cytotoxic lymphocytes remains incompletely understood.
Our data showed that FURIN-deﬁcient CTLs produced
more IFNg and showed an upregulation of CD69 activation
marker, but a careful analysis of for example their cytotoxic
potential, granzyme B, and perforin expressions needs fur-
ther studies.
In conclusion, our data demonstrate that FURIN expression
in T cells clearly modulates adaptive immune responses in both
untreated mice and in animals suffering from DMBA/TPA-
induced skin papillomas. This leads to accelerated tumor devel-
opment accompanied with aberrant T-cell cytokine production
in T-cell-speciﬁc FURIN KO mice. Our ﬁndings suggest that
inhibiting FURIN systematically, or speciﬁcally in T cells, may
promote the development of cancer types wherein a chronic
immune insult has a cancer provoking role. This is an impor-
tant aspect when considering FURIN inhibitors’ therapeutic
potential in human cancers.
Materials and methods
Mice
T-cell-speciﬁc FURIN conditional knockout (CD4cre KO) mice
on a C57BL/6 background have been described previously.14,27
Macrophage-speciﬁc FURIN conditional knockout mice
(LysMcre KO) were generated using a LysMcre C57BL/6 back-
ground.19,40 Mice were fed with standard laboratory pellets and
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water ad libitum. All animal experiments were performed in
accordance with protocols approved by the National Animal
Ethics Committee of Finland.
Skin tumor induction
Both FURIN KO strains, LysMcre and CD4cre, as well as their
respective littermate control C57BL/6 WT, LysM WT and CD4C
WT mice were treated with DMBA and TPA to induce skin
tumors as previously described.22 In brief, the backs of 8–14-
week-old mice were shaved and 24 h later 50 mg DMBA (7,12-
Dimethylbenz[a]anthracene) (Sigma, Dorset, UK) in 200 mL ace-
tone was applied topically on the shaved area of the dorsal skin.
After a week, the back skin of the mice was treated twice a week
with 5 mg TPA (12-O-tetradecanoylphorbol-13-acetate) (Sigma)
in 200 mL acetone for 16 or 21 weeks. The fur excluding tumors
was carefully shaved every 2 weeks. Tumors (1 mm in diameter
or larger) were counted twice a week and changes in tumor
development were recorded for each individual tumor.
Immunohistochemical (IHC) and TUNEL staining
Samples of back skin from sacriﬁced, shaved control mice or
mice at 43 h or week 17 of the tumor induction experiment
were collected and ﬁxed with 4% paraformaldehyde and embed-
ded in parafﬁn according to standard protocols. Hematoxylin/
eosin staining and DAB immunohistochemical staining (IHC)
was performed on 6-mm thick parafﬁn sections as previously
described.22 The following primary antibodies were used for
IHC: A0452 rabbit anti-CD3 (DakoCytomation, Glostrup, Den-
mark), MF48000 BM8 rat anti-F4/80 (Life Technologies Ltd.,
Paisley, UK), and 68672 rabbit anti-neutrophil elastase (AbCam,
Cambridge, UK). More detailed list of reagents, imaging, and
quantitation are described in the Supplementary methods.
Flow cytometry
For surface markers, the skin dLN cells were stained with anti-
bodies against mouse CD4, CD8, CD44, CD62L, and CD69 (all
from eBioscience, San Diego, California, USA). For intracellular
staining, isolated dLN cells were stimulated with PMA and Ca-
ionomycin for 4 h, and Brefeldin A and Monensin were applied
for the last 2 h of the stimulation. The cells were stained with
surface markers and subsequently ﬁxed overnight with Fixa-
tion/Permeabilization solution (from Foxp3/Transcription Fac-
tor Staining Buffer Set, eBioscience), permeabilized with
Permeabilization Buffer (eBioscience) and stained with intra-
cellular antibodies (IL-10, IFNg, IL-17A, Foxp3; all from eBio-
science), according to the manufacturer’s instructions. All cells
were analyzed with FACSCanto II (Becton, Dickinson and
Company, Franklin Lakes, New Jersey, USA), data analysis per-
formed with FlowJo software (Flowjo LLC, Ashland, Oregon,
USA).
Luminex and ELISA assays
Skin dLN cells from mice treated with DMBA/TPA for 17
weeks were cultured for 48 h in the presence of plate-bound
anti-CD3 antibody (10 mg/mL, clone 17A2, eBioscience) and
soluble anti-CD28 Ab (2 mg/mL, clone 37.51, eBioscience).
Multiplex cytokine/chemokine measurement was done from
the culture supernatants using ProCartaPlex assay (Mouse
Cytokine & Chemokine 26-plex, eBioscience) according to the
manufacturer’s instructions, and with Bio-Plex 200 instrument
(Bio-Rad). IFNg levels were determined from the cell culture
supernatants with a Ready-Set-Go! ELISA kit (eBioscience),
according to the manufacturer’s instructions.
Statistical analysis
Mean averages are shown with 95% conﬁdence intervals, in the
case of Fig. 1B with SEM. Immunohistochemistry data were
analyzed to determine if it was normally distributed (D’Agos-
tino & Pearson omnibus and Shapiro–Wilk normality tests).
Signiﬁcance at a given time point was calculated by two-tailed
Student’s t-test for normally distributed data. An a level less
than 0.05 was considered signiﬁcant. Tumor-free survival plot
data were analyzed by log-rank (Mantel-Cox) test and non-
normally distributed time course data were analyzed by non-
linear regression. Prism 6 (GraphPad Software, La Jolla Califor-
nia, USA) was used for a majority of the analyses and STATA
13.0 (StataCorp LP, College Station, Texas, USA:) statistical
analysis software was used for non-linear negative binomial
regression analysis, as indicated.
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